Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
dasatinib tyrosine-protein kinase abl1 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.59 approved,investigational multitarget,inhibitor
dasatinib tyrosine-protein kinase abl1 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.59 approved,investigational multitarget
dasatinib tyrosine-protein kinase abl1 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.59 approved,investigational multitarget,inhibitor
dasatinib tyrosine-protein kinase abl1 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.59 approved,investigational multitarget
dasatinib abelson tyrosine-protein kinase 2 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 1.24 approved,investigational multitarget
dasatinib abelson tyrosine-protein kinase 2 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 1.24 approved,investigational multitarget
dasatinib breakpoint cluster region protein small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.29 approved,investigational unknown
dasatinib breakpoint cluster region protein small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.29 approved,investigational inhibitor
dasatinib breakpoint cluster region protein small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.29 approved,investigational unknown
dasatinib breakpoint cluster region protein small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.29 approved,investigational inhibitor
dasatinib tyrosine-protein kinase btk small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.05 approved,investigational unknown
dasatinib tyrosine-protein kinase btk small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.05 approved,investigational unknown
dasatinib tyrosine-protein kinase csk small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib tyrosine-protein kinase csk small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib ephrin type-a receptor 2 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.64 approved,investigational antagonist
dasatinib ephrin type-a receptor 2 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.64 approved,investigational antagonist,inhibitor
dasatinib ephrin type-a receptor 2 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.64 approved,investigational antagonist
dasatinib ephrin type-a receptor 2 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.64 approved,investigational antagonist,inhibitor
dasatinib ephrin type-a receptor 5 small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib ephrin type-a receptor 5 small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib ephrin type-b receptor 4 small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib ephrin type-b receptor 4 small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib tyrosine-protein kinase fgr small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.22 approved,investigational inhibitor
dasatinib tyrosine-protein kinase fgr small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.22 approved,investigational inhibitor
dasatinib tyrosine-protein kinase frk small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.06 approved,investigational inhibitor
dasatinib tyrosine-protein kinase frk small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.06 approved,investigational inhibitor
dasatinib fyn tyrosine protein kinase NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.19 approved inhibitor
dasatinib fyn tyrosine protein kinase NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.19 approved unknown
dasatinib tyrosine-protein kinase fyn small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.19 approved,investigational multitarget
dasatinib tyrosine-protein kinase fyn small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.19 approved,investigational multitarget
dasatinib tyrosine-protein kinase fyn small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.19 approved,investigational multitarget,inhibitor
dasatinib fyn tyrosine protein kinase NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.19 approved unknown
dasatinib tyrosine-protein kinase fyn small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.19 approved,investigational multitarget,inhibitor
dasatinib fyn tyrosine protein kinase NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.19 approved inhibitor
dasatinib heat shock cognate 71 kda protein small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib heat shock cognate 71 kda protein small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib mast/stem cell growth factor receptor kit small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.45 approved,investigational antagonist
dasatinib mast/stem cell growth factor receptor kit small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.45 approved,investigational antagonist,inhibitor
dasatinib mast/stem cell growth factor receptor kit small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.45 approved,investigational antagonist,inhibitor
dasatinib mast/stem cell growth factor receptor kit small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.45 approved,investigational antagonist
dasatinib tyrosine-protein kinase lck small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.1 approved,investigational multitarget
dasatinib tyrosine-protein kinase lck small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.1 approved,investigational multitarget,inhibitor
dasatinib lck tyrosine protein kinase NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.1 approved inhibitor
dasatinib lck tyrosine protein kinase NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.1 approved unknown
dasatinib tyrosine-protein kinase lck small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.1 approved,investigational multitarget
dasatinib lck tyrosine protein kinase NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.1 approved inhibitor
dasatinib tyrosine-protein kinase lck small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.1 approved,investigational multitarget,inhibitor
dasatinib lck tyrosine protein kinase NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.1 approved unknown
dasatinib tyrosine-protein kinase lyn small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.04 approved,investigational inhibitor
dasatinib tyrosine-protein kinase lyn small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.04 approved,investigational inhibitor
dasatinib mitogen-activated protein kinase 14 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.02 approved,investigational unknown
dasatinib mitogen-activated protein kinase 14 small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.02 approved,investigational unknown
dasatinib nuclear receptor subfamily 4 group a member 3 small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib nuclear receptor subfamily 4 group a member 3 small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib platelet-derived growth factor receptor beta small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.12 approved,investigational antagonist,inhibitor
dasatinib platelet-derived growth factor receptor beta small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.12 approved,investigational antagonist,inhibitor
dasatinib platelet-derived growth factor receptor beta small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.12 approved,investigational antagonist
dasatinib platelet-derived growth factor receptor beta small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.12 approved,investigational antagonist
dasatinib amidophosphoribosyltransferase small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib amidophosphoribosyltransferase small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib proto-oncogene c-src NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.31 approved inhibitor
dasatinib proto-oncogene c-src NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.31 approved unknown
dasatinib proto-oncogene c-src NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.31 approved inhibitor
dasatinib proto-oncogene tyrosine-protein kinase src small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.31 approved,investigational multitarget
dasatinib proto-oncogene c-src NA Successful target TTD , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.31 approved unknown
dasatinib proto-oncogene tyrosine-protein kinase src small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.31 approved,investigational multitarget,inhibitor
dasatinib proto-oncogene tyrosine-protein kinase src small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.31 approved,investigational multitarget
dasatinib proto-oncogene tyrosine-protein kinase src small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.31 approved,investigational multitarget,inhibitor
dasatinib signal transducer and activator of transcription 5b small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 1.18 approved,investigational inhibitor
dasatinib signal transducer and activator of transcription 5b small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 1.18 approved,investigational inhibitor
dasatinib tyrosine-protein kinase yes small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.03 approved,investigational inhibitor
dasatinib tyrosine-protein kinase yes small molecule NA drugbank , DGIDB Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 0.03 approved,investigational inhibitor
dasatinib mitogen-activated protein kinase kinase kinase mlt small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
dasatinib mitogen-activated protein kinase kinase kinase mlt small molecule NA drugbank Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Lymph[MeSHID:D008196]
Philadelphia Chromosome[MeSHID:D010677]
Blast Phase[MeSHID:D001752]
Severe Acute Respiratory Syndrome[MeSHID:D045169]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Middle East Respiratory Syndrome[MeSHID:D018352]
Myeloid Leukemia
Chronic[MeSHID:D015464]		 NA approved,investigational unknown
click here to return to the previous page